Stockscreener 앱 받기
53.84
0.34%
0.18
시간 외 거래:
53.89
0.05
+0.09%
전일 마감가:
$53.66
열려 있는:
$53.67
하루 거래량:
1.52M
Relative Volume:
0.80
시가총액:
$4.31B
수익:
-
순이익/손실:
$-269.44M
주가수익비율:
-14.36
EPS:
-3.75
순현금흐름:
$-262.63M
1주 성능:
-0.07%
1개월 성능:
+27.64%
6개월 성능:
+43.08%
1년 성능:
+74.69%
1일 변동 폭
$53.63
$53.87
1주일 범위
$53.53
$54.08
52주 변동 폭
$21.34
$58.40
Akero Therapeutics Inc Stock (AKRO) Company Profile
명칭
Akero Therapeutics Inc
전화
650-487-6488
주소
601 GATEWAY BOULEVARD, SUITE 350, SOUTH SAN FRANCISCO, CA
AKRO을(를) 다른 주식과 비교
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
AKRO
Akero Therapeutics Inc
|
53.84 | 4.30B | 0 | -269.44M | -262.63M | -3.75 |
|
VRTX
Vertex Pharmaceuticals Inc
|
416.81 | 104.76B | 11.39B | 3.64B | 3.50B | 13.99 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
481.67 | 63.06B | 2.46B | -319.09M | -52.09M | -2.4669 |
|
REGN
Regeneron Pharmaceuticals Inc
|
578.05 | 60.32B | 14.21B | 4.46B | 3.56B | 39.69 |
|
ARGX
Argen X Se Adr
|
843.66 | 51.55B | 3.06B | 1.28B | 447.35M | 19.67 |
|
INSM
Insmed Inc
|
165.76 | 34.49B | 398.11M | -1.03B | -868.57M | -5.7032 |
Akero Therapeutics Inc Stock (AKRO) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2025-09-04 | 재개 | H.C. Wainwright | Buy |
| 2025-08-04 | 개시 | TD Cowen | Buy |
| 2025-01-30 | 업그레이드 | BofA Securities | Neutral → Buy |
| 2025-01-27 | 재확인 | H.C. Wainwright | Buy |
| 2024-11-18 | 개시 | Citigroup | Buy |
| 2024-04-22 | 재개 | BofA Securities | Neutral |
| 2023-09-19 | 개시 | Cantor Fitzgerald | Overweight |
| 2023-08-28 | 개시 | UBS | Buy |
| 2023-01-27 | 업그레이드 | Morgan Stanley | Equal-Weight → Overweight |
| 2022-09-14 | 업그레이드 | Evercore ISI | In-line → Outperform |
| 2021-10-19 | 다운그레이드 | Morgan Stanley | Overweight → Equal-Weight |
| 2021-09-10 | 개시 | BofA Securities | Buy |
| 2021-02-26 | 개시 | Guggenheim | Buy |
| 2020-09-10 | 개시 | Morgan Stanley | Overweight |
| 2020-07-20 | 재확인 | H.C. Wainwright | Buy |
| 2020-07-07 | 개시 | Chardan Capital Markets | Buy |
| 2020-07-01 | 재확인 | H.C. Wainwright | Buy |
| 2020-03-02 | 개시 | H.C. Wainwright | Buy |
| 2020-02-10 | 개시 | Canaccord Genuity | Buy |
| 2019-07-15 | 개시 | Evercore ISI | Outperform |
| 2019-07-15 | 개시 | JP Morgan | Overweight |
| 2019-07-15 | 개시 | Jefferies | Buy |
| 2019-07-15 | 개시 | ROTH Capital | Buy |
모두보기
Akero Therapeutics Inc 주식(AKRO)의 최신 뉴스
Is Akero Therapeutics Inc. stock a buy before product launchesFed Meeting & Smart Money Movement Alerts - newser.com
Akero Therapeutics (AKRO) Jumps 16% on $5.2-Billion Novo Nordisk Merger - MSN
How Akero Therapeutics Inc. stock compares to industry benchmarksTake Profit & Safe Capital Growth Stock Tips - Trung tâm Dự báo KTTV quốc gia
Will earnings trigger a reversal in Akero Therapeutics Inc.Market Risk Report & Reliable Trade Execution Plans - newser.com
Custom watchlist performance reports with Akero Therapeutics Inc.Market Trend Summary & Daily Oversold Stock Bounce Ideas - newser.com
Advanced analytics toolkit walkthrough for Akero Therapeutics Inc.Weekly Trading Summary & Community Verified Trade Signals - newser.com
Is Akero Therapeutics Inc a good long term investmentHigh Dividend Yield Stocks & Access Free Risk Analysis Before You Invest - earlytimes.in
SHAREHOLDER RIGHTS ALERT: Halper Sadeh LLC Investigates TRUE, AKRO, PCH, ATXS on Behalf of Shareholders - GlobeNewswire Inc.
BRODSKY & SMITH SHAREHOLDER UPDATE: Notifying Investors of - GlobeNewswire
BRODSKY & SMITH SHAREHOLDER UPDATE: Notifying Investors of the Following Investigations: Akero Therapeutics, Inc. (NasdaqAKRO), CoreCard Corporation (NYSECCRD), PB Bankshares, Inc. (Nasdaq - GlobeNewswire Inc.
Can a trend reversal in Akero Therapeutics Inc. lead to recoveryEarnings Recap Summary & High Conviction Buy Zone Alerts - newser.com
Will Akero Therapeutics Inc. stock gain from lower inflationBear Alert & Low Drawdown Momentum Trade Ideas - newser.com
Understanding Momentum Shifts in (AKRO) - news.stocktradersdaily.com
Novo Nordisk’s Akero Therapeutics Buy Targets Eli Lilly’s Lead - MarketBeat
Will Akero Therapeutics Inc. stock reach Wall Street targetsJuly 2025 PostEarnings & Real-Time Buy Zone Alerts - newser.com
Is Akero Therapeutics Inc. stock bottoming outEarnings Overview Summary & Free High Return Stock Watch Alerts - newser.com
Akero Therapeutics Inc. (AKRO) Stock Price | Live Quotes & Charts | NASDAQ - StocksToTrade
Akero Therapeutics CEO Cheng sells $1.62m in shares By Investing.com - Investing.com Australia
Biotech Fund Beating 92% of Peers Sees More M&A Deals to Come - Bloomberg.com
Akero Therapeutics CEO Cheng sells $1.62m in shares - Investing.com
Novo Nordisk to acquire Akero Therapeutics and its promising phase 3 FGF21 analogue to expand MASH portfolio - Zenopa
Akero Therapeutics, Inc. $AKRO Stake Trimmed by Aberdeen Group plc - MarketBeat
Is Akero Therapeutics Inc. forming a bottoming baseJuly 2025 WrapUp & Long-Term Safe Return Strategies - newser.com
StockWatch: Novo Nordisk Raises MASH Bet with Up-to-$5.2B Akero Acquisition - Genetic Engineering and Biotechnology News
Novo Nordisk to Acquire Akero Therapeutics for $4.7B - contractpharma.com
TD Cowen Downgrades Akero Therapeutics to Hold From Buy, Adjusts Price Target to $58 From $76 - MarketScreener
Akero Therapeutics, Inc. (AKRO) Stock Analysis: Exploring a 20% Upside Potential in Biotech - DirectorsTalk Interviews
Novo Nordisk to acquire Akero Therapeutics for up to USD 5.2 billion - Medical Dialogues
Real time breakdown of Akero Therapeutics Inc. stock performanceMarket Activity Summary & Daily Momentum Trading Reports - newser.com
Novo Nordisk to acquire Akero Therapeutics for $5.2 billion - Indian Pharma Post
The week in pharma: action, reaction and insight – week to October 10 - The Pharma Letter
Akero Therapeutics (NASDAQ:AKRO) Sees Unusually-High Trading VolumeShould You Buy? - MarketBeat
Akero Therapeutics (NASDAQ:AKRO) Lowered to Hold Rating by Wolfe Research - MarketBeat
Akero Therapeutics (NASDAQ:AKRO) Cut to "Neutral" at HC Wainwright - MarketBeat
Lifesci Capital Downgrades Akero Therapeutics (NASDAQ:AKRO) to Hold - MarketBeat
Akero Therapeutics (NASDAQ:AKRO) Lowered to "Sell" Rating by Wall Street Zen - MarketBeat
Akero Therapeutics (NASDAQ:AKRO) Insider Sells $576,000.00 in Stock - MarketBeat
Akero Therapeutics Investor Alert By The Former Attorney General Of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Akero Therapeutics, Inc.AKRO - Business Wire
Akero Therapeutics (NASDAQ:AKRO) Shares Gap UpShould You Buy? - MarketBeat
$HAREHOLDER ALERT: The M&A Class Action Firm Announces An - GlobeNewswire
Akero Therapeutics Acquired by Novo Nordisk for $5.2B - The Globe and Mail
Akero Therapeutics (NASDAQ:AKRO) Cut to Hold at Jefferies Financial Group - MarketBeat
Akero Therapeutics (NASDAQ:AKRO) Downgraded by Canaccord Genuity Group to Hold - MarketBeat
Quantitative breakdown of Akero Therapeutics Inc. recent moveWeekly Profit Report & Free Low Drawdown Momentum Trade Ideas - newser.com
OVID Stock Soars 39% in a Month Following Upbeat Epilepsy Study Data - Yahoo Finance
This Keysight Analyst Is No Longer Bullish; Here Are Top 5 Downgrades For Friday - Benzinga
How to recover losses in Akero Therapeutics Inc. stockJuly 2025 Intraday Action & Weekly Chart Analysis and Trade Guides - newser.com
Novo Nordisk: New CEO Executing on Focused Strategy With Akero Acquisition - Morningstar Canada
Can Novo Nordisk's Aggressive Deal-Making Offset Semaglutide Reliance? - Zacks Investment Research
Wolfe Research Downgrades Akero Therapeutics (AKRO) to Peer Perf - GuruFocus
Wolfe Research Downgrades Akero Therapeutics to Peer Perform From Outperform - MarketScreener
Akero Therapeutics Inc (AKRO) 재무 분석
매출
순이익
현금흐름
주당 순 이익
1.84%
0.50%
자본화:
|
볼륨(24시간):